Impact of the protein corona on nanomaterial immune response and targeting ability.


Journal

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
ISSN: 1939-0041
Titre abrégé: Wiley Interdiscip Rev Nanomed Nanobiotechnol
Pays: United States
ID NLM: 101508311

Informations de publication

Date de publication:
07 2020
Historique:
received: 23 10 2019
revised: 15 01 2020
accepted: 16 01 2020
pubmed: 1 2 2020
medline: 10 6 2021
entrez: 1 2 2020
Statut: ppublish

Résumé

Over the last decade nanomaterials have had a major impact on human health for the early detection and treatment of many diseases. The future success of clinically translatable nanomaterials lies in the combination of several functionalities to realize a personalized medical experience for patients. To maintain promises, concerns arising from toxic potential and off-target accumulation of nanomaterials must be addressed first. Upon introduction to a complex biological system (e.g., following systemic administration), nanomaterials interact with all the encountered biomolecules and form the protein corona, a complex coating of plasma proteins that provides them with a totally new biological identity. As the protein corona controls the nanomaterial behavior in vivo, a precise knowledge of the relationship between biological identity and physiological response is needed but not yet achieved. Based on impressive progress made thus far, this review critically discusses how the protein corona activates immune response and influences the targeted delivery of nanomaterials. Furthermore, we comment on emerging strategies to manipulate protein binding in order to promote formation of designer artificial coronas and achieve a desired therapeutic outcome. We conclude by debating challenges that must be overcome to obtain widespread clinical adoption of nanomaterials. This article is categorized under: Nanotechnology Approaches to Biology > Cells at the Nanoscale Toxicology and Regulatory Issues in Nanomedicine > Toxicology of Nanomaterials Therapeutic Approaches and Drug Discovery > Emerging Technologies.

Identifiants

pubmed: 32003104
doi: 10.1002/wnan.1615
doi:

Substances chimiques

Protein Corona 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1615

Informations de copyright

© 2020 Wiley Periodicals, Inc.

Auteurs

Luca Digiacomo (L)

Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.

Daniela Pozzi (D)

Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.

Sara Palchetti (S)

Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.

Alessandra Zingoni (A)

Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.

Giulio Caracciolo (G)

Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH